17,261 trials
Acinar Cell Adenocarcinoma of the Pancreas · Duct Cell Adenocarcinoma of the Pancreas · Stage IV Pancreatic Cancer
Primary: Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib) — 80 milligrams
COVID-19
Primary: Day 28 Ventilator Free Survival — 0.79; 0.86 proportion of participants
Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Incidence of Relapse — 30 Percentage of participants
Melanoma · Metastatic Melanoma · Mucosal Melanoma
Primary: Number of Participants With Treatment-related Adverse Events Per Study Arm — 0; 0; 0; 0 Participants
Prostate Cancer · Prostate Adenocarcinoma · Prostate Cancer Metastatic
Primary: Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer on a Per-patient Basis Confirmed by Histopathology. — 87.3 percentage of times value is…
Urethral Stricture
Primary: Number of Subjects With Complication After Treatment — 0 Participants
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
Moderate to Severe Ulcerative Colitis
Primary: Change From Baseline for Adapted Mayo Score: 0.2 mg Versus Placebo — -2.60; -1.95 score on a scale
Choroideremia · CHM (Choroideremia) Gene Mutations
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 5; 5 Participants
Osteoarthritis
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.67; -1.76 score on a scale
Obesity
Primary: Percentage Change in Body Weight From Baseline to Week 46 — -6.19; -12.51; -13.22; -14.94 Percentage change — p=<0.0001
Chronic Low-back Pain
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.69; -1.77 score on a scale
Depression · Major Depressive Disorder · Dysthymic Disorder
Primary: Hemoglobin A1c at 6 Months — 4.94; 4.88 % (percentage of total hemoglobin) — p=0.64
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
Esophageal Cancer · Gastric Cancer
Primary: Efficacy — 4; 18; 12; 8 Participants